How much funding has Hemab Therapeutics raised?

Hemab Therapeutics has raised $347.0M in total funding, most recently a series c round.

Who are Hemab Therapeutics's investors?

Hemab Therapeutics's investors include Sofinnova Partners, Access Biotechnology, Novo Holdings, Avoro Ventures, Deep Track Capital, Invus.

When was Hemab Therapeutics founded?

Hemab Therapeutics was founded in 2019.

Where is Hemab Therapeutics headquartered?

Hemab Therapeutics is headquartered in Cambridge.

What industry is Hemab Therapeutics in?

Hemab Therapeutics operates in Biotech, Healthcare.

How many employees does Hemab Therapeutics have?

Hemab Therapeutics has 11-50 employees.

Hemab Therapeutics

Cambridge · Founded 2019 · $347.0M raised

Biotech

Healthcare

Headquarters: Cambridge
Employees: 11–50
Founded: 2019
Business Model: B2B

Website: hemab.com
Total Funding: $347.0M
Last Round: $157.0M Series CMar 2026
Rounds: 3

About

Hemab Therapeutics is a clinical-stage biopharmaceutical company developing novel prophylactic therapies for serious, underserved bleeding and thrombotic disorders. Its lead program, sutacimig, is a bispecific antibody in Phase 2 trials for Glanzmann Thrombasthenia, and HMB-002 targets Von Willebrand Disease. Founded in 2019 by former Novo Nordisk researchers and backed by Novo Holdings, the company is advancing a pipeline aimed at enabling prevention rather than just management of rare bleeding conditions.

Summary

Hemab Therapeutics is a Biotech company based in Cambridge, founded in 2019. It has raised $347.0M in total across 3 rounds, most recently a $157.0M Series C round in Mar 2026. Investors include Sofinnova Partners, Access Biotechnology and Novo Holdings.